Autopsy report · NCT05743270

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Replimune, Inc.
Sponsor type: Industry
Conditions: Squamous Cell Carcinoma of Head and Neck; Locally Advanced Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: RP3; CCRT(concurrent chemoradiation therapy); carboplatin and paclitaxel; nivolumab
Participants: 0
Sites: 34
Countries: Czechia, France, Germany, Greece, Poland, Spain, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.